Siddiqui Mashfiqul A, Seng Chusheng, Tan Mann Hong
Department of Orthopaedic Surgery, Singapore General Hospital, Singapore.
J Orthop Surg (Hong Kong). 2014 Apr;22(1):108-10. doi: 10.1177/230949901402200127.
To determine the risk factors for recurrence of giant cell tumours (GCTs) of bone.
Medical records of 29 men and 29 women (mean age, 34 years) treated for primary (n=53) or recurrent (n=5) GCTs of bone and followed up for a mean of 40.2 months were reviewed. The tumours were located in the distal femur (n=18), proximal tibia (n=10), proximal femur (n=8), distal radius (n=7), proximal fibula (n=4), distal ulna (n=3), calcaneum (n=3), sacrum (n=2), vertebra (n=1), metatarsal (n=1), and distal humerus (n=1). 26 patients had pathological fractures, 12 had cortical break, and 20 had neither. The Campanacci grades of the tumours were I (n=1), II (n=18), and III (n=33); the grades of the remaining 6 tumours were unknown because radiographs were unavailable. The Enneking stages of the tumours were 1 (n=51), 2 (n=6), and 3 (n=1). Treatment included curettage and cementation (n=29), curettage, cementation, and adjuvant treatment with distilled water or liquid nitrogen for bones without fracture (n=18), wide resection for extensive soft tissue involvement (n=9), and amputation (n=2) for a recurrent GCT of the distal femur and a primary GCT of the calcaneus. Reconstruction included cementation (n=27), bone grafting (n=7), cementation/bone grafting with internal fixation (n=14), reconstruction with endoprosthesis (n=3), and none (n=7).
19 patients had recurrence after a mean of 23.1 months. The overall recurrence-free survival at years 1, 2, and 3 were 86%, 79%, and 72%, respectively. Recurrence did not correlate with patient age (p=0.20), primary or recurrent tumour at presentation (p=0.12), Campanacci grade (p=0.10), Enneking stage (p=0.54), or presence of pathological fracture (p=0.28). Compared to GCTs at other locations, GCTs in the proximal tibia were more likely to recur (27% vs. 60%, p=0.04).
GCTs of the proximal tibia are more likely to recur than those at other locations.
确定骨巨细胞瘤(GCT)复发的危险因素。
回顾了29名男性和29名女性(平均年龄34岁)的病历,这些患者接受了原发性(n = 53)或复发性(n = 5)骨巨细胞瘤的治疗,平均随访40.2个月。肿瘤位于股骨远端(n = 18)、胫骨近端(n = 10)、股骨近端(n = 8)、桡骨远端(n = 7)、腓骨近端(n = 4)、尺骨远端(n = 3)、跟骨(n = 3)、骶骨(n = 2)、椎体(n = 1)、跖骨(n = 1)和肱骨远端(n = 1)。26例患者发生病理性骨折,12例有皮质骨破裂,20例两者均无。肿瘤的Campanacci分级为I级(n = 1)、II级(n = 18)和III级(n = 33);其余6例肿瘤的分级未知,因为无法获得X线片。肿瘤的Enneking分期为1期(n = 51)、2期(n = 6)和3期(n = 1)。治疗方法包括刮除植骨术(n = 29)、对于无骨折的骨骼采用刮除植骨术并辅以蒸馏水或液氮治疗(n = 18)、对于广泛软组织受累行广泛切除术(n = 9)以及对股骨远端复发性骨巨细胞瘤和跟骨原发性骨巨细胞瘤行截肢术(n = 2)。重建方法包括植骨术(n = 27)、骨移植(n = 7)、植骨/骨移植加内固定(n = 14)、采用人工关节假体重建(n = 3)以及未行重建(n = 7)。
19例患者平均在23.1个月后复发。1年、2年和3年的总体无复发生存率分别为86%、79%和72%。复发与患者年龄(p = 0.20)、初次就诊时的原发性或复发性肿瘤(p = 0.12)、Campanacci分级(p = 0.10)、Enneking分期(p = 0.54)或病理性骨折的存在(p = 0.28)均无相关性。与其他部位的骨巨细胞瘤相比,胫骨近端的骨巨细胞瘤更易复发(27%对60%,p = 0.04)。
胫骨近端的骨巨细胞瘤比其他部位的更易复发。